Cyclacel Pharmaceuticals Analyst Ratings
Roth MKM Maintains Buy on Cyclacel Pharmaceuticals, Lowers Price Target to $11
Roth MKM Maintains Buy on Cyclacel Pharmaceuticals, Raises Price Target to $21
Cyclacel Pharmaceuticals Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Sonnet BioTherapeutics Holdings (SONN), Aravive (ARAV) and Cyclacel Pharmaceuticals (CYCC)
Oppenheimer Adjusts Cyclacel Pharmaceuticals Price Target to $8 From $10, Maintains Outperform Rating
Oppenheimer Maintains Outperform on Cyclacel Pharmaceuticals, Lowers Price Target to $8
Analysts Offer Insights on Healthcare Companies: Cyclacel Pharmaceuticals (CYCC), CymaBay Therapeutics (CBAY) and Immuneering (IMRX)
No Data